Hoppe I, Maass H
Dtsch Med Wochenschr. 1982 Dec 24;107(51-52):1966-8. doi: 10.1055/s-2008-1070241.
The risk of hepatitis from prothrombin complex (pooled human clotting preparation) was retrospectively analysed. Of 39 patients who had undergone cardiac surgery, 22 (56%) developed hepatitis, while in those had not received pooled preparations the rate was only 5%. Although the proportion of multiple transfusions was significantly higher among the recipients of clotting preparations, it was found that the decisive hepatitis-inducing factor was the pooled preparation, not the transfusion blood. Contrary to earlier results, all cases were of the non-A, non-B type. The frequency of carriers of the causative virus is apparently not different from that with B virus. Thus both virus types must have occurred at similar frequency in earlier pooled clotting preparations. Since, furthermore, there seems to be no difference in their infectivity and their penetration in the population at large is likely to be similarly low, unrecognised double-infections in recipients of pooled clotting preparations were probably frequent before the introduction of recent methods of demonstrating hepatitis B.
对凝血酶原复合物(混合人凝血制剂)所致肝炎的风险进行了回顾性分析。在39例接受心脏手术的患者中,22例(56%)发生了肝炎,而未接受混合制剂的患者中这一比例仅为5%。尽管在接受凝血制剂的患者中多次输血的比例明显更高,但发现决定性的致肝炎因素是混合制剂,而非输血。与早期结果相反,所有病例均为非甲非乙型。致病病毒携带者的频率显然与B病毒携带者无异。因此,在早期的混合凝血制剂中,两种病毒类型的出现频率想必相似。此外,由于它们的传染性似乎并无差异,且在普通人群中的传播率可能同样较低,在采用近期检测乙型肝炎的方法之前,混合凝血制剂接受者中未被识别的双重感染可能很常见。